Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma

Sphingolipid (SL) metabolism alterations have been frequently reported in cancer including in melanoma, a bad-prognosis skin cancer. In normal cells, de novo synthesized ceramide is mainly converted to sphingomyelin (SM), the most abundant SL, by sphingomyelin synthase 1 (SMS1) and, albeit to a less...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Fatima Bilal, Anne Montfort, Julia Gilhodes, Virginie Garcia, Joëlle Riond, Stéphane Carpentier, Thomas Filleron, Céline Colacios, Thierry Levade, Ahmad Daher, Nicolas Meyer, Nathalie Andrieu-Abadie, Bruno Ségui
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2019-04-01
Edice:	Frontiers in Pharmacology
Témata:	sphingolipids ceramide glucosylceramide prognosis biomarker cancer
On-line přístup:	https://www.frontiersin.org/article/10.3389/fphar.2019.00443/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!